Engraftment of human primary acute myeloid leukemia defined by integrated genetic profiling in NOD/SCID/IL2rynull mice for preclinical ceramide-based therapeutic evaluation.
J Leuk 2014; 2(3):146
Acute Myeloid Leukemia (AML) is a highly heterogeneous and poor prognosis disease with few available therapeutic options. Novel advances are urgently needed, however effective models to test experimental therapeutics have been lacking. Recently, NOD/SCID/IL2rγnull (NSG) mice were shown to engraft primary human AML in a manner that recapitulated the natural disease and its progression. Additionally, integrated genomic profiling was used to refine risk stratification of AML. In this study, we demonstrated the engraftment of molecularly defined primary AML in NSG mice. We showed that AML that express DNMT3A mutations, which predict for adverse outcome, engrafted with exceptional efficacy. Lastly, we demonstrated that human AML-engrafted NSG mice can be effectively used to study novel ceramide-based therapeutics. Ceramide is a bioactive sphingolipid that has been implicated as an inducer of apoptosis. Elevation in cancer cell ceramide levels either via exogenous delivery or by provoking intracellular ceramide generation is the goal of ceramide-based therapeutics. In this study, we used the human AML-engrafted NSG mouse model to evaluate nanoliposomal short-chain C6-ceramide and a nanoliposomal formulation of the ceramide-inducer tamoxifen. Altogether, the NSG model is likely to prove invaluable in the study of novel agents, such as ceramide-based therapeutics, with the ability to define therapeutic activity against specific molecularly defined and risk stratified AML. J Leuk 2014; 2(3):146
Engraftment of human primary acute myeloid leukemia defined by integrated genetic profiling in NOD/SCID/IL2rynull mice for preclinical ceramide-based therapeutic evaluation. J Leuk 2014; 2(3):146